Hong Kong Stock Movement | TYK MEDICINES-B (02410) Surges Over 13% in Morning Session as Aimdotinib Mesylate Tablets Included in Priority Review List

Stock News01-30

TYK MEDICINES-B (02410) surged more than 13% during the morning session. As of the time of writing, the stock was up 8.94%, trading at HK$13.52, with a turnover of HK$40.70 million.

The company announced that its self-developed Class 1 new drug, Aimdotinib Mesylate Tablets (TY-9591 tablets), has been included in the Priority Review品种名单 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).

This drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion or exon 21 substitution mutations and are accompanied by central nervous system metastases.

Inclusion in the Priority Review signifies a comprehensive acceleration of the evaluation process for Aimdotinib Mesylate Tablets, potentially leading to an earlier market launch and providing a new treatment option for patients in China.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199886224?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-30 09:52","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199886224","market":"other","top_or_hot":-1,"title":"Hong Kong Stock Movement | TYK MEDICINES-B (02410) Surges Over 13% in Morning Session as Aimdotinib Mesylate Tablets Included in Priority Review List","media":"Stock News","content":"<p>TYK MEDICINES-B (02410) surged more than 13% during the morning session. As of the time of writing, the stock was up 8.94%, trading at HK$13.52, with a turnover of HK$40.70 million.</p>\n<p>The company announced that its self-developed Class 1 new drug, Aimdotinib Mesylate Tablets (TY-9591 tablets), has been included in the Priority Review品种名单 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).</p>\n<p>This drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion or exon 21 substitution mutations and are accompanied by central nervous system metastases.</p>\n<p>Inclusion in the Priority Review signifies a comprehensive acceleration of the evaluation process for Aimdotinib Mesylate Tablets, potentially leading to an earlier market launch and providing a new treatment option for patients in China.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hong Kong Stock Movement | TYK MEDICINES-B (02410) Surges Over 13% in Morning Session as Aimdotinib Mesylate Tablets Included in Priority Review List</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHong Kong Stock Movement | TYK MEDICINES-B (02410) Surges Over 13% in Morning Session as Aimdotinib Mesylate Tablets Included in Priority Review List\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2026-01-30 09:52</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>TYK MEDICINES-B (02410) surged more than 13% during the morning session. As of the time of writing, the stock was up 8.94%, trading at HK$13.52, with a turnover of HK$40.70 million.</p>\n<p>The company announced that its self-developed Class 1 new drug, Aimdotinib Mesylate Tablets (TY-9591 tablets), has been included in the Priority Review品种名单 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).</p>\n<p>This drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion or exon 21 substitution mutations and are accompanied by central nervous system metastases.</p>\n<p>Inclusion in the Priority Review signifies a comprehensive acceleration of the evaluation process for Aimdotinib Mesylate Tablets, potentially leading to an earlier market launch and providing a new treatment option for patients in China.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"VT","symbol_name":"世界全股市ETF-Vanguard","start_time":0,"source_url":"","article_id":"1199886224","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199886224","pubTimestamp":1769737939,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"TYK MEDICINES-B (02410) surged more than 13% during the morning session. As of the time of writing, the stock was up 8.94%, trading at HK$13.52, with a turnover of HK$40.70 million. The company...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"159938":"医药","VT":"世界全股市ETF-Vanguard","BK1515":"抗疫概念","BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","BK1574":"生物医药B类股","09939":"开拓药业-B","02410":"同源康医药-B"},"translate_title":"港股动向|泰克医药-B(02410)早盘大涨超13%甲磺酸艾多替尼片纳入优先审评名单","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"159938":1,"02410":1,"09939":1,"VT":1},"content_text":"TYK MEDICINES-B (02410) surged more than 13% during the morning session. As of the time of writing, the stock was up 8.94%, trading at HK$13.52, with a turnover of HK$40.70 million.\nThe company announced that its self-developed Class 1 new drug, Aimdotinib Mesylate Tablets (TY-9591 tablets), has been included in the Priority Review品种名单 by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).\nThis drug is intended for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) who have EGFR exon 19 deletion or exon 21 substitution mutations and are accompanied by central nervous system metastases.\nInclusion in the Priority Review signifies a comprehensive acceleration of the evaluation process for Aimdotinib Mesylate Tablets, potentially leading to an earlier market launch and providing a new treatment option for patients in China.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"2","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199886224","isCrawlerRequest":true}